Kurin Launches Kurin Jet, Redefining the Blood Culture Contamination Device Market

Kurin, Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced today the full-scale launch of Kurin Jet™, which has joined the Kurin product family. The original member of the Kurin family, now named the Kurin Lock^®, is the market-leading product in this space. Jet provides a significant technological advancement over Lock.

“We had earlier announced a limited commercial release and have been thrilled with responses from customers using Jet,” said Bob Rogers, CEO of Kurin, Inc. “Feedback from those using Jet has been very positive with clinicians amazed at how fast Jet works, and they appreciate the greater control it allows. Automated manufacturing has started, and we are now able to provide this next generation product more widely. Jet can be used with direct to media, syringe draw, direct venipuncture and PIV applications.”

“Lock became the market-leading product because of its small size, small amount of blood required and ease of use. Compliance is the key to improving clinical outcomes and the increased speed and control make Jet even easier to use, helping hospitals address this important clinical problem.

Kurin’s revolutionary approach to the contaminated blood culture problem is based on elegantly simple, intuitive designs that require no additional user steps. Like the Lock, Jet passively sidelines potential contaminants during blood culture collection. Lock and Jet both provide a better and more sustainable approach than active, conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Lock and Jet give clinicians the tools they need to address these problems.